Tetrabenazine was recently approved to treat this disease, functioning by inhibiting VMAT-2. While this disease's mechanism is not fully understood, it is known to result in nuclear inclusion bodies, which may explain the toxicity caused by its characteristic protein misfolding. On a larger scale, it damages the striatum in
Tetrabenazine was recently approved to treat this disease, functioning by inhibiting VMAT-2. While this disease's mechanism is not fully understood, it is known to result in nuclear inclusion bodies, which may explain the toxicity caused by its characteristic protein misfolding. On a larger scale, it damages the striatum in the brain, likely responsible for its symptoms of chorea. Marked by a long CAG repeat on chromosome 4 resulting in a mutant namesake protein, identify this neurodegenerative autosomal dominant disease whose onset comes around age 40.
Tetrabenazine was recently approved to treat this disease, functioning by inhibiting VMAT-2.
{Huntington's} disease [or {Huntington's} chorea]